Smith D R, Chang B S, Johnson C E
Am J Hosp Pharm. 1978 Jan;35(1):58-61.
A crossover, randomized, eight-week trial using eight adult volunteers was undertaken to (1) determine the efficacy of aluminum hydroxide in decreasing gastrointestinal phosphate absorption, (2) compare the effectiveness of "with meal" and "between meal" dosing schedules, and (3) compare the effectiveness of the capsule and liquid dosage forms. Four treatments, each with a daily dose of approximately 6 g, were taken on a three-times-a-day regimen. The effectiveness of the treatment regimens was measured by using two variables: the decrease in total urinary phosphorus excretion, and the increase in the percent tubular reabsorption of phosphorus (TRP). Aluminum hydroxide treatment produced a significant change in urinary phosphorus excretion (p less than 0.0005) and in percent TRP (p less than 0.0005). For the study population, total urinary phosphorus excretion was the determining factor in changing the percent TRP. The increase in TRP and the decrease in total urinary phosphorus excretion was of the same degree regardless of dosage form or dosage schedule. Aluminum hydroxide was effective in decreasing phosphorus absorption as measured in this study. It appears that aluminum hydroxide capsules could be used with equal efficacy as the liquid dosage form in controlling hyperphosphatemia in patients with chronic renal failure who will not comply with a treatment program using the liquid.
采用8名成年志愿者进行了一项为期8周的交叉随机试验，目的是：(1) 确定氢氧化铝在减少胃肠道磷吸收方面的疗效；(2) 比较“餐中”和“餐间”给药方案的有效性；(3) 比较胶囊剂型和液体剂型的有效性。四种治疗方法，每种每日剂量约6 g，采用一日三次的给药方案。通过两个变量来衡量治疗方案的有效性：尿总磷排泄量的减少以及磷肾小管重吸收率（TRP）百分比的增加。氢氧化铝治疗使尿磷排泄量（p<0.0005）和TRP百分比（p<0.0005）产生了显著变化。对于研究人群，尿总磷排泄量是改变TRP百分比的决定因素。无论剂型或给药方案如何，TRP的增加和尿总磷排泄量的减少程度相同。在本研究中，氢氧化铝在减少磷吸收方面是有效的。对于那些不依从使用液体剂型治疗方案的慢性肾衰竭患者，氢氧化铝胶囊在控制高磷血症方面似乎可以与液体剂型具有同等疗效。
